Molecular profiles of small cell lung cancer subtypes: Therapeutic implications
Anna Schwendenwein, Zsolt Megyesfalvi, Nándor Bárány, Zsuzsanna Valkó, Edina Bugyik, Christian Lang, Bence Ferencz, Sándor Paku, András Lantos, János Fillinger, Melinda Rezeli, György Marko‐Varga, Krisztina Bogos, Gabriella Gálffy, F Rényi-Vámos, Mir Alireza Hoda, Walter Klepetko, Konrad Höetzenecker, Viktória László, Balázs Döme
Abstract
Small cell lung cancer (SCLC; accounting for approximately 13%-15% of all lung cancers) is an exceptionally lethal malignancy characterized by rapid doubling time and high propensity to metastasize. In contrast to the increasingly personalized therapies in other types of lung cancer, SCLC is still regarded as a homogeneous disease and the prognosis of SCLC patients remains poor. Recently, however, substantial progress has been made in our understanding of SCLC biology. Advances in genomics and development of new preclinical models have facilitated insights into the intratumoral heterogeneity and specific genetic alterations of this disease. This worldwide resurgence of studies on SCLC has ultimately led to the development of novel subtype-specific classifications primarily based on the neuroendocrine features and distinct molecular profiles of SCLC. Importantly, these biologically distinct subtypes might define unique therapeutic vulnerabilities. Herein, we summarize the current knowledge on the molecular profiles of SCLC subtypes with a focus on their potential clinical implications.